In vitro synergistic effect of farnesol and human gingival cells against Candida albicans

Yeast

Volumn 23, Issue 9, 2006, Pages 673-687

  Saidi, Said ^a   Luitaud, Cyril ^a   Rouabhia, Mahmoud ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Antifungal; Candida albicans; Candidiasis; Epithelial cells; Farnesol; Oral mucosa

Indexed keywords

FARNESOL;

ARTICLE; CANDIDA ALBICANS; CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; EPITHELIUM CELL; FIBROBLAST; FUNGUS GROWTH; FUNGUS HYPHAE; GINGIVA; GROWTH INHIBITION; HOST CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL;

CANDIDA ALBICANS; CANDIDIASIS, ORAL; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; EPITHELIAL CELLS; FARNESOL; FIBROBLASTS; GINGIVA; HUMANS; MOUTH DISEASES;

CANDIDA ALBICANS;

EID: 33747082908     PISSN: 0749503X     EISSN: 10970061     Source Type: Journal    
DOI: 10.1002/yea.1389     Document Type: Article

References (55)

1. Andrian F, Grenier D, Rouabhia M. 2005. Porphyromonas gingivalis lipopolysaccharide induces shedding of syndecan-1 expressed by gingival epithelial cells. J Cell Physiol 204: 178-183.
2. Barousse MM, Steele C, Dunlap K, et al. 2001. Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis 184: 1489-1493.
3. Blijlevens NMA, Donnelly JP, DePauw BE. 2005. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 36: 703-707.
4. Blijlevens NMA, van't Land B, Donnelly JP, M'Rabet L, de Pauw BE. 2004. Measuring mucosal damage induced by cytotoxic therapy. Support Care Cancer 12: 227-233.
5. Bos JD, Kapsenberg ML. 1993. The skin immune system: progress in cutaneous biology. Immunol Today 14: 75-78.
6. Burke YD, Stark MJ, Roach SL, Sen SE, Crowell PL. 1997. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids 32: 151-156.
7. Bustamante CI. 2005. Treatment of Candida infection: a view from the trenches! Curr Opin Infect Dis 18: 490-495.
8. Calderone RA, Fonzi WA. 2001. Virulence factors of Candida albicans. Trends Microbiol 9: 327-335.
9. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. 1998. Increasing complexity of Ras signalling. Oncogene 17: 1395-413.
10. Cao YY, Cao YB, Xu Z, et al. 2005. cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother 49: 584-589.
11. Del Villar K, Dorin D, Sattler I, et al. 1996. C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Biochem Soc Trans 24: 709-713.
12. Dongari-Bagtzoglou A, Fidel PL Jr. 2005. The host cytokine responses and protective immunity in oropharyngeal candidiasis. J Dent Res 84: 966-977.
13. Edwards PA, Ericsson J. 1999. Sterols and isoprenoids: signalling molecules derived from the cholesterol biosynthetic pathway. Ann Rev Biochem 68: 157-185.
14. Enjalbert B, Whiteway M. 2005. Release from quorum-sensing molecules triggers hyphal formation during Candida albicans resumption of growth. Eukaryot Cell 4: 1203-1210.
15. Fetter A, Partisani M, Koenig H, Kremer M, Lang JM. 1993. Asymptomatic oral Candida albicans carriage in HIV infection: frequency and predisposing factors. J Oral Pathol Med 22: 57-59.
16. Fidel PL Jr. 2002. Distinct protective host defenses against oral and vaginal candidiasis. Med Mycol 40: 359-375.
17. Fradin C, Hube B. 2003. Tissue infection and site-specific gene expression in Candida albicans. Adv Appl Microbiol 53: 271-290.
18. Gibbs JB, Graham SL, Hartman GD, et al. 1997. Farnesyltransferase inhibitors versus Ras inhibitors. Curr Opin Chem Biol 1: 197-203.
19. Gottfredsson M, Cox GM, Indridason OS, et al. 1999. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 180: 534-537.
20. Gow NA, Brown A, Odds FC. 2002. Fungal morphogenesis and host invasion. Curr Opin Microbiol 5: 366-371.
21. Grunler J, Ericsson J, Dallner G. 1994. Branch-point in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylate proteins. Biochim Biophys Acta 1212: 259-277.
22. Hemmerlin A, Reents R, Mutterer J, et al. 2005. Monitoring farnesol-induced toxicity in tobacco BY-2 cells with a fluorescent analog. Arch Biochem Biophys (in press).
23. Horn TL, Long L, Cwik MJ, et al. 2005. Modulation of hepatic and renal drug metabolizing enzyme activities in rats by subchronic administration of farnesol. Chem Biol Interact 152: 79-99.
24. Hornby JM, Jensen EC, Lisec AD, et al. 2001. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 67: 2982-2992.
25. Hornby JM, Kebaara BW, Nickerson KW. 2003. Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zaragozic acid B. Antimicrob Agents Chemother 47: 2366-2369.
26. Hudes GR, Szarka CE, Adams A, et al. 2000. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin Cancer Res 6: 3071-3080.
27. Kruppa M, Krom BP, Chauhan N, et al. 2004. The two-component signal transduction protein Chk1p regulates quorum sensing in Candida albicans. Eukaryot Cell 3: 1062-1065.
28. Kuriyama T, Williams DW, Bagg J, et al. 2005. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol 20: 349-353.
29. Leigh JE, Barousse M, Swoboda RK, et al. 2001. Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis 183: 277-285.
30. McAnally JA, Jung M, Mo H. 2003. Farnesyl-O-acetylhydroquinone and geranyl-O-acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells. Cancer Lett 202: 181-192.
31. Miller MB, Bassler BL. 2001. Quorum sensing in bacteria. Annu Rev Microbiol 55: 165-199.
32. Mosel DD, Dumitru R, Hornby JM, Atkin AL, Nickerson KW. 2005. Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum. Appl Environ Microbiol 71: 4938-4940.
33. Mostefaoui Y, Bart C, Frenette M, Rouabhia M. 2004. Candida albicans and Streptococcus salivarius modulate IL-6, IL-8, and TNF-α expression and secretion by engineered human oral mucosa cells. Cell Microbiol 6: 1085-1096.
34. Mostefaoui Y, Claveau I, Ross G, Rouabhia M. 2002. Tissue structure, and IL-1β, IL-8 and TNF-α secretions after contact by engineered human oral mucosa with dentifrices. J Clin Periodontol 29: 1035-1041.
35. Odds FC. 1988. Candida and Candidosis: A Review and Bibliography. Baillière Tindall: London.
36. Pei ZM, Ghassemian M, Kwak CM, McCourt P, Schroeder JI. 1998. Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss. Science 282: 287-290.
37. Pfaller MA, Boyken L, Hollis RJ, et al. 2005. In vitro activities of anidulafungin against more than 2500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 43: 5425-5427.
38. Poon GK, Vigushin D, Griggs LJ, et al. 1996. Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry. Drug Metab Dispos 24: 565-571.
39. Presland RB, Dale BA. 2000. Epithelial structural proteins of the skin and oral cavity: function in health and disease. Crit Rev Oral Biol Med 11: 383-408.
40. Presland RB, Jurevic RJ. 2002. Making sense of the epithelial barrier: what molecular biology and genetics tell us about the functions of oral mucosal and epidermal tissues. J Dent Educ 66: 564-574.
41. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. 2002. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 68: 5459-5463.
42. Reznik DA. 2005. Oral manifestations of HIV disease. Top HIV Med 13: 143-148.
43. Rouabhia M, Jobin N, Doucet R Jr, Bergeron J, Auger A. 1994. CD36(+)-dendritic epidermal cells: a putative actor in the cutaneous immune system. Cell Transplant 3: 529-536.
44. Rouabhia M, Ross G, Page N, Chakir J. 2002. Interleukin-18 and gamma interferon production by oral epithelial cells in response to exposure to Candida albicans or lipopolysaccharide stimulation. Infect Immun 70: 7073-7080.
45. Rouabhia M, Schaller M, Corbucci C, et al. 2005. Virulence of the fungal pathogen Candida albicans requires the five isoforms of protein mannosyltransferases. Infect Immun 73: 4571-4580.
46. Schmidt-Westhausen AM, Bendick C, Reichart PA, Samaranayake LP. 2004. Oral candidosis and associated Candida species in HIV-infected Cambodians exposed to antimycotics. Mycoses 47: 435-441.
47. Selvaratnam L, Cruchley AT, Navsaria H, et al. 2001. Permeability barrier properties of oral keratinocyte cultures: a model of intact human oral mucosa. Oral Dis 7: 252-258.
48. Shibuya K, Coulson WF, Wollman JS, et al. 2001. Histopathology of cryptococcosis and other fungal infections in patients with acquired immunodeficiency syndrome. Int J Infect Dis 5: 78-85.
49. Smith DJ, Taubman MA. 1992. Ontogeny of immunity to oral microbiota in humans. Crit Rev Oral Biol Med 3: 109-133.
50. Staab JF, Bradway SD, Fidel PL, Sundstrom P. 1999. Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science 283: 1535-1538.
51. Suzuki N, Urano J, Tamanoi F. 1998. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci USA 95: 15356-15361.
52. Vazquez JA. 2000. Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials 1: 47-59.
53. Wargovich MJ, Jimenez A, McKee K, et al. 2000. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 21: 1149-1155.
54. Wilkieson C, Samaranayake LP, MacFarlane TW, Lamey PJ, MacKenzie D. 1991. Oral candidosis in the elderly in long term hospital care. J Oral pathol Med 20: 13-16.
55. Wright MM, Henneberry AL, Lagace TA, Ridgway ND, McMaster CR. 2001. Uncoupling farnesol-induced apoptosis from its inhibition of phosphatidylcholine synthesis. J Biol Chem 276: 25254-25261.